Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis
Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis Aug 4 (Reuters) - Pfizer PFE.N beat Wall Street estimates for second-quarter profit on Tuesday, driven by strong demand for its blood thinner, Eliquis.
On an adjusted basis, the company reported a profit of 77 cents per share, compared with analysts' estimates of 68 cents per share, according to data compiled by LSEG.
(Reporting by Mariam Sunny and Mrinalika Roy in Bengaluru; Editing by Anil D'Silva)
Recent news on Pfizer
See all newsFactbox: Pharma sector doubles down on AI to slash costs, timelines
Focus: Beauty giants target 'Ozempic face' as boom in obesity drugs opens new market
Eli Lilly hits record high as healthcare stocks rally
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Factbox: Major drugmakers turn to China for licensing deals